Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.
Looking for growth in 2020 and beyond? Here are the latest ASX growth stock ideas, stories and news from our team at Rask Media. We think it’s fair to say that Australia’s ASX growth stocks are some of the best in the world, given their potential for international growth and the fact that many Australian companies also offer their dividends with franking credits.
The key catalyst, of course, was the Fed meeting. While the Fed kept rates on hold as widely expected, the ‘dot plot’ of Fed policy expectations retained a further rate hike this year – and one less rate cut in 2024.
Up 42%, is Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) a growth stock? Maybe, but probably not.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
NAOS’ Robert Miller dives into the case for Maxiparts Ltd (ASX:MXI), and offers an overview of Supply Network (ASX:SNL) and Bapcor (ASX:BAP).
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -1.37% to 7065.20.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.46% to 7163.30.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
The local share market fell for a second straight day on Tuesday, ahead of a flurry of central bank meetings, and following the release of a set of minutes from the Reserve Bank of Australia that were taken as implying that the local central bank is considered raising rates.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60.
The key catalyst, of course, was the Fed meeting. While the Fed kept rates on hold as widely expected, the ‘dot plot’ of Fed policy expectations retained a further rate hike this year – and one less rate cut in 2024.
Up 42%, is Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) a growth stock? Maybe, but probably not.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
NAOS’ Robert Miller dives into the case for Maxiparts Ltd (ASX:MXI), and offers an overview of Supply Network (ASX:SNL) and Bapcor (ASX:BAP).
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -1.37% to 7065.20.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.46% to 7163.30.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
The local share market fell for a second straight day on Tuesday, ahead of a flurry of central bank meetings, and following the release of a set of minutes from the Reserve Bank of Australia that were taken as implying that the local central bank is considered raising rates.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
